236 related articles for article (PubMed ID: 34844263)
41. Safety and immunogenicity of a third dose of mRNA-1273 vaccine among cancer patients.
Giuliano A; Kuter B; Pilon-Thomas S; Whiting J; Mo Q; Leav B; Sirak B; Cubitt C; Dukes C; Isaacs-Soriano K; Kennedy K; Ball S; Dong N; Jain A; Hwu P; Lancet J
Cancer Commun (Lond); 2023 Jul; 43(7):749-764. PubMed ID: 37377402
[TBL] [Abstract][Full Text] [Related]
42. Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies.
Chung DJ; Shah GL; Devlin SM; Ramanathan LV; Doddi S; Pessin MS; Hoover E; Marcello LT; Young JC; Boutemine SR; Serrano E; Sharan S; Momotaj S; Margetich L; Bravo CD; Papanicolaou GA; Kamboj M; Mato AR; Roeker LE; Hultcrantz M; Mailankody S; Lesokhin AM; Vardhana SA; Knorr DA
Blood Cancer Discov; 2021 Nov; 2(6):568-576. PubMed ID: 34778797
[TBL] [Abstract][Full Text] [Related]
43. mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant.
Parry H; Tut G; Bruton R; Faustini S; Stephens C; Saunders P; Bentley C; Hilyard K; Brown K; Amirthalingam G; Charlton S; Leung S; Chiplin E; Coombes NS; Bewley KR; Penn EJ; Rowe C; Otter A; Watts R; D'Arcangelo S; Hallis B; Makin A; Richter A; Zuo J; Moss P
Elife; 2021 Sep; 10():. PubMed ID: 34586068
[TBL] [Abstract][Full Text] [Related]
44. Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies.
Bergamaschi C; Pagoni M; Rosati M; Angel M; Tzannou I; Vlachou M; Darmani I; Ullah A; Bear J; Devasundaram S; Burns R; Baltadakis I; Gigantes S; Dimopoulos MA; Pavlakis GN; Terpos E; Felber BK
Front Immunol; 2022; 13():899972. PubMed ID: 35693807
[TBL] [Abstract][Full Text] [Related]
45. A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.
Noori M; Azizi S; Abbasi Varaki F; Nejadghaderi SA; Bashash D
Int Immunopharmacol; 2022 Sep; 110():109046. PubMed ID: 35843148
[TBL] [Abstract][Full Text] [Related]
46. Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals.
Collier AY; Yu J; McMahan K; Liu J; Atyeo C; Ansel JL; Fricker ZP; Pavlakis M; Curry MP; Jacob-Dolan C; Patel H; Sellers D; Barrett J; Rowe M; Ahmad K; Gompers A; Aguayo R; Chandrashekar A; Alter G; Hacker MR; Barouch DH
J Infect Dis; 2022 Apr; 225(7):1124-1128. PubMed ID: 34792136
[TBL] [Abstract][Full Text] [Related]
47. Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab.
Gallo A; Capuano R; Donnarumma G; Bisecco A; Grimaldi E; Conte M; d'Ambrosio A; Coppola N; Galdiero M; Tedeschi G
Neurol Sci; 2021 Sep; 42(9):3523-3526. PubMed ID: 34128150
[TBL] [Abstract][Full Text] [Related]
48. Single-cell profiling of T and B cell repertoires following SARS-CoV-2 mRNA vaccine.
Sureshchandra S; Lewis SA; Doratt BM; Jankeel A; Coimbra Ibraim I; Messaoudi I
JCI Insight; 2021 Dec; 6(24):. PubMed ID: 34935643
[TBL] [Abstract][Full Text] [Related]
49. Immunogenicity and reactogenicity of homologous mRNA-based and vector-based SARS-CoV-2 vaccine regimens in patients receiving maintenance dialysis.
Karakizlis H; Nahrgang C; Strecker K; Chen J; Aly M; Slanina H; Schüttler CG; Esso I; Wolter M; Todorova D; Jessen S; Adamik A; Ronco C; Seeger W; Weimer R; Sester M; Birk HW; Husain-Syed F
Clin Immunol; 2022 Mar; 236():108961. PubMed ID: 35227871
[TBL] [Abstract][Full Text] [Related]
50. Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis.
Reyes-Leiva D; López-Contreras J; Moga E; Pla-Juncà F; Lynton-Pons E; Rojas-Garcia R; Turon-Sans J; Querol L; Olive M; Álvarez-Velasco R; Caballero-Ávila M; Carbayo Á; Vesperinas-Castro A; Domingo P; Illa I; Gallardo E; Cortés-Vicente E
Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35728947
[TBL] [Abstract][Full Text] [Related]
51. Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy.
Marty PK; Van Keulen VP; Erskine CL; Shah M; Hummel A; Stachowitz M; Fatis S; Granger D; Block MS; Duarte-García A; Warrington KJ; Theel ES; Zhou X; Zeng H; Specks U; Escalante P; Peikert T
Front Immunol; 2022; 13():834981. PubMed ID: 35154159
[TBL] [Abstract][Full Text] [Related]
52. Can Individuals with Suboptimal Antibody Responses to Conventional Antiviral Vaccines Acquire Adequate Antibodies from SARS-CoV-2 mRNA Vaccination?
Ogura W; Ohtsuka K; Matsuura S; Okuyama T; Matsushima S; Yamasaki S; Miyagi H; Sekiguchi K; Ohnishi H; Watanabe T
Viruses; 2022 May; 14(5):. PubMed ID: 35632698
[TBL] [Abstract][Full Text] [Related]
53. Vaccination for SARS-CoV-2 in Hematological Patients.
Riccardi N; Falcone M; Yahav D
Acta Haematol; 2022; 145(3):257-266. PubMed ID: 35220303
[TBL] [Abstract][Full Text] [Related]
54. Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study.
Haydu JE; Maron JS; Redd RA; Gallagher KME; Fischinger S; Barnes JA; Hochberg EP; Johnson PC; Takvorian RW; Katsis K; Portman D; Ruiters J; Sechio S; Devlin M; Regan C; Blumenthal KG; Banerji A; Judd AD; Scorsune KJ; McGree BM; Sherburne MM; Lynch JM; Weitzman JI; Lei M; Kotton CN; Dighe AS; Maus MV; Alter G; Abramson JS; Soumerai JD
Blood Adv; 2022 Mar; 6(6):1671-1683. PubMed ID: 35073571
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study.
Molica S; Giannarelli D; Lentini M; Zappala D; Mannella A; Loiacono D; Gianfelici V; Panduri G; Gariani I; Minchella P; Talarico F; Levato L
Chemotherapy; 2022; 67(2):91-95. PubMed ID: 34872098
[TBL] [Abstract][Full Text] [Related]
56. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern.
van Gils MJ; van Willigen HDG; Wynberg E; Han AX; van der Straten K; Burger JA; Poniman M; Oomen M; Tejjani K; Bouhuijs JH; Verveen A; Lebbink R; Dijkstra M; Appelman B; Lavell AHA; Caniels TG; Bontjer I; van Vught LA; Vlaar APJ; Sikkens JJ; Bomers MK; Russell CA; Kootstra NA; Sanders RW; Prins M; de Bree GJ; de Jong MD;
Cell Rep Med; 2022 Jan; 3(1):100486. PubMed ID: 35103254
[TBL] [Abstract][Full Text] [Related]
57. BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus.
Moyon Q; Sterlin D; Miyara M; Anna F; Mathian A; Lhote R; Ghillani-Dalbin P; Breillat P; Mudumba S; de Alba S; Cohen-Aubart F; Haroche J; Pha M; Boutin THD; Chaieb H; Flores PM; Charneau P; Gorochov G; Amoura Z
Ann Rheum Dis; 2022 Apr; 81(4):575-583. PubMed ID: 34607791
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A Contemporary Cohort Analysis.
Abid MB; Rubin M; Szabo A; Longo W; Fenske TS; McCoy C; Lorge A; Abedin S; D'Souza A; Dhakal B; Shah NN; Hamadani M
Transplant Cell Ther; 2024 Mar; 30(3):285-297. PubMed ID: 38142942
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response.
Tychala A; Meletis G; Katsimpourlia E; Gkeka I; Dimitriadou R; Sidiropoulou E; Skoura L
Hum Vaccin Immunother; 2021 Dec; 17(12):5148-5149. PubMed ID: 34714711
[TBL] [Abstract][Full Text] [Related]
60. Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies.
Re D; Seitz-Polski B; Brglez V; Carles M; Graça D; Benzaken S; Liguori S; Zahreddine K; Delforge M; Bailly-Maitre B; Verrière B; Chamorey E; Barrière J
Nat Commun; 2022 Feb; 13(1):864. PubMed ID: 35165284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
